Loading…
Back To Schedule
Tuesday, September 20 • 1:00pm - 1:45pm
Panel: Gene Editing Therapies

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Tweet Share
It's been 10 years since Jennifer Doudna and Emmanuelle Charpentier’s Nobel Prize-winning discovery of the ability to edit genes using CRISPR. The publication of their paper set the biotech world aflame. So how is gene editing being applied to human medicine?

In this panel, we’ll hear from some of the leading biotechs at the forefront of bringing gene editing into the clinic—the promise, the challenges and the pitfalls of this emerging modality.
Moderator
avatar for Angus Liu

Angus Liu

Senior Writer, Fierce Biotech
Angus is a senior staff writer with Questex’s Life Sciences group. He earned his Master’s at Northwestern University’s Medill School of Journalism, where he worked as a health reporter besides learning pertinent skills in magazine editing and interactive production. Prior to... Read More →

Speakers
avatar for Jason Gehrke

Jason Gehrke

Senior Director and Head of Immunology, Beam Therapeutics
Jason Gehrke serves as Head of Immunology at Beam Therapeutics, where he leads the discovery and development of multiplex base edited cell therapies for the treatment of cancers and autoimmune disease. Jason previously served as Head of New Opportunities at Beam where he applied base... Read More →
avatar for Michael Holmes Ph.D.

Michael Holmes Ph.D.

Chief Scientific Officer, Tessera
Michael joined Tessera in December 2021 as Chief Scientific Officer. Dr. Holmes has over 20 years of experience working on the development and clinical translation of different genome editing- and gene therapy-based strategies for the treatment of inherited and acquired diseases... Read More →
avatar for Craig Mickanin

Craig Mickanin

Executive Director in Chemical Biology and Therapeutics and global head of the Genomic Sciences Group, Novartis Institutes for BioMedical Research
Craig Mickanin is an executive director in Chemical Biology and Therapeutics and global head of the Genomic Sciences Group at the Novartis Institutes for BioMedical Research. He has been with Novartis for 24 years, most of which he has spent studying cell & gene therapies. In his... Read More →
avatar for David Lebwohl, M.D.

David Lebwohl, M.D.

Executive Vice President, Chief Medical Officer, Intellia Therapeutics, Inc.
Dr. David Lebwohl’s career spans three decades in the biopharmaceutical industry, successfully bringing novel medicines through all phases of clinical trials and global regulatory approvals. During his career, he has overseen multiple full-scale development programs with more than... Read More →

Tuesday September 20, 2022 1:00pm - 1:45pm EDT
  Early-Stage Development